COVID-19  in patients with chronic inflammatory rheumatic joint disease

Tidsskr Nor Laegeforen. 2021 Oct 11;141(2021-14). doi: 10.4045/tidsskr.21.0362. Print 2021 Oct 12.ABSTRACTBACKGROUND: Since patients with chronic inflammatory rheumatic joint diseases may be more prone to infections, we wished to investigate the incidence of COVID-19 in this group, and explore the possible significance of factors related to the rheumatic disease, the patient or the treatment.MATERIAL AND METHOD: Altogether 27 907 patients registered in the Norwegian Arthritis Registry (NorArthritis) were linked to the Norwegian Surveillance System for Communicable Diseases and the Norwegian Intensive Care and Pandemic Registry in order to find the incidence of COVID-19 in 2020, and the proportion of patients who were hospitalised. A standardised incidence ratio (SIR) was calculated by comparing with sex and age-specific incidence in the general population. Logistic regression analysis was used to investigate whether diagnosis, age, sex, disease activity, comorbidity or drug therapy had any bearing on the incidence.RESULTS: A total of 185 of the patients in NorArthritis tested positive for COVID-19, of whom 10 % were hospitalised. The incidence was lower than in the general population (SIR 0.84; 95 % confidence interval (CI): 0.72-0.97, P = 0.02). Young age and low disease activity were associated with higher incidence of infection. The other factors had no significant effect.INTERPRETATION: The fact that the incidence of COVID-19 was lower than in the general population, and ...
Source: Tidsskrift for den Norske Laegeforening - Category: General Medicine Authors: Source Type: research

Related Links:

New Brunswick, N.J. (October 19, 2021) – Johnson &Johnson (NYSE: JNJ) today announced results for third-quarter 2021. “Our third-quarter results demonstrate solid performance across Johnson &Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health,” said Alex Gorsky, Chairman and Chief Executive Officer. “In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Financial Source Type: news
Tidsskr Nor Laegeforen. 2021 Oct 11;141(2021-14). doi: 10.4045/tidsskr.21.0362. Print 2021 Oct 12.ABSTRACTBACKGROUND: Since patients with chronic inflammatory rheumatic joint diseases may be more prone to infections, we wished to investigate the incidence of COVID-19 in this group, and explore the possible significance of factors related to the rheumatic disease, the patient or the treatment.MATERIAL AND METHOD: Altogether 27 907 patients registered in the Norwegian Arthritis Registry (NorArthritis) were linked to the Norwegian Surveillance System for Communicable Diseases and the Norwegian Intensive Care and Pandemic Regi...
Source: Tidsskrift for den Norske Laegeforening - Category: General Medicine Authors: Source Type: research
In a recent series of articles, we explored the latest moves of Tech Giants like Amazon, NVIDIA and Microsoft in the field of digital health. Analysing these recent developments can give us a better idea regarding where they are focusing the efforts, and how it might shape the future path of healthcare.  But equally, if not more, strong players in this field are pharmaceutical giants, as their resources and influence can significantly shape or alter the course of this path. As such, we are kickstarting a new series of articles focusing on the digital health efforts of 14 global pharma companies. While those heavywe...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Future of Medicine Future of Pharma digital health novartis pfizer J&J big pharma Johnson&Johnson Bayer Source Type: blogs
CONCLUSION: We report the successful use of telemedicine services in the evaluation and management of rheumatic diseases in the current COVID-19 pandemic situation.PMID:34630561 | PMC:PMC8497142 | DOI:10.1155/2021/5558826
Source: International Journal of Telemedicine and Applications - Category: Information Technology Authors: Source Type: research
AbstractWe congratulate the authors for the excellent review, not only restricted to recently approved therapies, on the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) (1). However, it is our opinion that some aspects that currently affect our medical practice merit further commentary.The pandemic of COVID-19 has generated unique challenges in the therapy of SSc-ILD, especially impacting the decision to start treatment. While there is no evidence suggesting that cyclophosphamide or rituximab can reduce mortality in SSc-ILD (2), these drugs have been associated with higher incidence of seriou...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: LETTER TO THE EDITOR Source Type: research
AbstractWe appreciate the insights and concerns shared by Dr. Jain et al. regarding the use of rituximab (RTX) and cyclophosphamide (CYC) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), as outlined in the American College of Rheumatology/Vasculitis Foundation (ACR/VF) guideline for the treatment of ANCA-associated vasculitis (AAV) [1]. These concerns are timely given the ongoing COVID-19 pandemic.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: REPLY Source Type: research
AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 19 (COVID-19) pandemic, which is deeply affecting the whole world. In this new case for the scientific world, scientists are investigating the etiopathogenesis of viral infection-induced damage and have started to focus on the short and long-term immune system effects and alterations after SARS-CoV-2 infection. The case is here reported of a 53-year-old female patient with acute monoarthritis after SARS-CoV-2 infection, who responded adequately to 150  mg/day diclofenac treatment, and the available ca...
Source: Rheumatology International - Category: Rheumatology Source Type: research
More News: Arthritis | COVID-19 | General Medicine | Intensive Care | Norway Health | Pandemics | Rheumatology